Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

PTN | Palatin Technologies Inc.

Index	-	P/E	-	EPS (ttm)	-2.53	Insider Own	4.79%	Shs Outstand	11.66M	Perf Week	15.13%
Market Cap	20.16M	Forward P/E	-	EPS next Y	-0.48	Insider Trans	0.00%	Shs Float	10.97M	Perf Month	-17.06%
Income	-27.54M	PEG	-	EPS next Q	-0.41	Inst Own	7.63%	Short Float / Ratio	4.02% / 4.74	Perf Quarter	-16.67%
Sales	4.85M	P/S	4.16	EPS this Y	30.04%	Inst Trans	14.22%	Short Interest	0.44M	Perf Half Y	-36.13%
Book/sh	0.01	P/B	152.17	EPS next Y	72.88%	ROA	-101.99%	Target Price	83.33	Perf Year	-70.44%
Cash/sh	0.95	P/C	1.84	EPS next 5Y	-	ROE	-335.84%	52W Range	1.43 - 6.40	Perf YTD	-31.64%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-3801.97%	52W High	-72.66%	Beta	1.01
Dividend %	-	Quick Ratio	0.99	Sales past 5Y	147.86%	Gross Margin	77.79%	52W Low	22.38%	ATR	0.18
Employees	34	Current Ratio	1.08	Sales Q/Q	128.60%	Oper. Margin	-689.91%	RSI (14)	46.54	Volatility	12.15% 10.13%
Optionable	Yes	Debt/Eq	8.08	EPS Q/Q	31.69%	Profit Margin	-567.44%	Rel Volume	0.58	Prev Close	1.71
Shortable	Yes	LT Debt/Eq	4.54	Earnings	Sep 28 BMO	Payout	-	Avg Volume	93.09K	Price	1.75
Recom	1.00	SMA20	-3.98%	SMA50	-15.90%	SMA200	-32.82%	Volume	54,235	Change	2.34%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-15	Reiterated	Canaccord Genuity	Buy	$4 → $6
Jan-12-15	Reiterated	ROTH Capital	Buy	$6 → $4
May-23-12	Initiated	Noble Financial	Buy
Jan-23-07	Initiated	Next Generation	Buy	$5

Today 08:35AM	Palatin Technologies, Inc. (AMEX:PTN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Sep-29-23 01:34AM	Q4 2023 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
Sep-28-23 07:30AM	Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update (PR Newswire) -9.09%
Sep-22-23 04:00PM	Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023 (PR Newswire) -5.66%
Sep-07-23 04:00PM	Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
07:30AM	Loading…
07:30AM	Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease (PR Newswire)
Aug-10-23 07:30AM	Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment (PR Newswire) -5.50%
Aug-08-23 07:30AM	Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study (PR Newswire) +8.20%
Aug-07-23 07:30AM	Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth for Vyleesi® (PR Newswire) +23.86%
Aug-04-23 07:30AM	Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference (PR Newswire)
Jul-11-23 07:30AM	Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results (PR Newswire)
May-30-23 07:30AM	Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference (PR Newswire)
May-17-23 01:39PM	Palatin Technologies, Inc. (AMEX:PTN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.43%
01:33AM	Q3 2023 Palatin Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
May-16-23 08:45AM	Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Loading…
07:30AM	Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-15-23 09:05AM	Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +17.19%
May-11-23 05:25PM	TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023 (PR Newswire)
May-09-23 05:45PM	Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference (PR Newswire)
May-08-23 04:04PM	Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar (PR Newswire) +7.62%
May-01-23 04:00PM	Palatin Technologies to Host Key Opinion Leader Webinar (PR Newswire)
Apr-27-23 07:30AM	Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference (PR Newswire)
Apr-25-23 07:30AM	Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma (PR Newswire) -8.20%
Apr-19-23 07:30AM	Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results (PR Newswire)
Apr-18-23 07:30AM	Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences (PR Newswire)
Mar-02-23 07:30AM	Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease (PR Newswire) -9.17%
Feb-28-23 07:30AM	Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension (PR Newswire) +18.50%
Feb-15-23 07:30AM	Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update (PR Newswire)
07:30AM	Loading…
Feb-10-23 07:30AM	Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023 (PR Newswire)
Jan-26-23 05:45PM	Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Jan-19-23 07:30AM	Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease (PR Newswire)
Jan-18-23 07:30AM	Palatin Receives $4.7 Million of Non-Dilutive Funding (PR Newswire)
Jan-10-23 07:30AM	Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions (PR Newswire) +16.53%
Jan-05-23 07:30AM	Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results (PR Newswire)
Nov-14-22 08:55AM	Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.71%
07:30AM	Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-10-22 08:55AM	Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-09-22 06:45PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
05:16PM	Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022 (PR Newswire)
Nov-08-22 07:25PM	Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.96%
Nov-07-22 05:15PM	YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.24%
Oct-31-22 09:30AM	Palatin Announces $10 Million Registered Direct Offering (PR Newswire)
Oct-27-22 07:05AM	Swedish Orphan Biovitrum (BIOVF) Beats Q3 Earnings Estimates (Zacks)
Oct-24-22 05:32PM	Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting (PR Newswire) +8.05%
Oct-20-22 07:30AM	First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial (PR Newswire)
Oct-17-22 07:30AM	Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD) (PR Newswire)
Oct-13-22 07:30AM	Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results (PR Newswire)
Sep-29-22 03:45PM	Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference (PR Newswire)
01:31PM	Palatin to Participate in Ladenburg Thalmann Healthcare Conference (PR Newswire)
Sep-22-22 11:00AM	Edited Transcript of PTN.A earnings conference call or presentation 22-Sep-22 3:00pm GMT (Thomson Reuters StreetEvents) -12.36%
09:22AM	Palatin Technologies Shares Drop After Wider Than Expected Quarterly Loss (Benzinga)
07:30AM	Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update (PR Newswire)
Sep-19-22 04:15PM	Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022 (PR Newswire)
Sep-08-22 07:30AM	Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis (PR Newswire) +26.20%
Sep-02-22 10:28AM	3 Penny Stocks That Could 10X by 2023 (InvestorPlace) +6.98%
Aug-19-22 07:30AM	Palatin Announces Intent to Effect Reverse Stock Split (PR Newswire) -15.65%
Aug-16-22 07:30AM	Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease (PR Newswire) -6.55%
Jul-26-22 07:30AM	Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter (PR Newswire)
Jul-13-22 10:53AM	Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals (Zacks) -5.10%
May-17-22 08:45AM	Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update (PR Newswire)
May-16-22 07:15AM	PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.38%
May-12-22 08:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock (PR Newswire)
May-11-22 09:02AM	Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022 (PR Newswire)
May-10-22 08:45AM	Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-09-22 05:15PM	Berkeley Lights, Inc. (BLI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-05-22 06:05PM	Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.20%
May-02-22 01:02PM	Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference (PR Newswire)
Apr-21-22 07:30AM	Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022 (PR Newswire)
Apr-13-22 08:24AM	Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar? (Zacks)
Mar-03-22 07:30AM	Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease (PR Newswire)
Feb-15-22 07:30AM	Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update (PR Newswire) +7.20%
Feb-14-22 08:15PM	Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Feb-10-22 05:25PM	Ultragenyx (RARE) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.27%
07:30AM	Palatin to Report Second Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on February 15, 2022 (PR Newswire)
Feb-09-22 03:01PM	Palatin Technologies, Inc. (PTN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks) +5.09%
Feb-08-22 02:38PM	Rainey & Randall Investment Management Inc. ... (GuruFocus.com)
Jan-21-22 07:30AM	Palatin Announces Presentation at the 2022 Crohn's and Colitis Congress (PR Newswire)
Jan-07-22 10:59AM	Palatin to Present at H.C. Wainwright BioConnect Conference (PR Newswire)
Dec-29-21 10:18AM	Palatin (PTN) Begins Phase III Study For Dry Eye Disease (Zacks)
Dec-28-21 07:30AM	Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease (PR Newswire)
Dec-06-21 03:55PM	Keep Your Eye On Palatin Technologies as $5 Price Target Gets Attention (InvestorPlace)
10:00AM	Here's Why Palatin Technologies, Inc. (PTN) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Nov-30-21 07:30AM	Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide (PR Newswire) -16.39%
Nov-24-21 11:20AM	PTN Stock Alert: Why One Analyst Sees 1,371% Upside for Palatin Technologies (InvestorPlace) +49.36%
Nov-15-21 07:30AM	Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update (PR Newswire)
Nov-10-21 04:30PM	Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021 (PR Newswire)
Oct-22-21 07:30AM	Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting (PR Newswire)
Sep-29-21 07:30AM	Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update (PR Newswire) -5.86%
Sep-27-21 07:30AM	Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting (PR Newswire)
Sep-24-21 07:30AM	Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September 29, 2021 (PR Newswire)
Sep-15-21 07:30AM	Palatin to Present Peptides Platform at the TIDES USA Conference (PR Newswire)
Sep-13-21 07:00AM	Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual Conference (PR Newswire)
Jul-22-21 05:28PM	Palatin Announces Presentation at the Eyecelerator@ASCRS Conference (PR Newswire)
Jul-08-21 04:15PM	Palatin Announces Adjournment of Annual Meeting of Stockholders (PR Newswire)
Jun-29-21 07:30AM	Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease (PR Newswire) +23.49%
Jun-28-21 07:30AM	Palatin Announces New Additions to Its Senior Leadership Team (PR Newswire)

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DUNTON ALAN W	Director	Dec 21	Sale	2.97	200	594	41,420	Dec 23 05:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTN | Palatin Technologies Inc.

Upgrade your FINVIZ experience